JPH08239364A - ５−アシル−１，４−ジヒドロピリジンの使用法 - Google Patents

５−アシル−１，４−ジヒドロピリジンの使用法

Info

Publication number
JPH08239364A
JPH08239364A JP7346237A JP34623795A JPH08239364A JP H08239364 A JPH08239364 A JP H08239364A JP 7346237 A JP7346237 A JP 7346237A JP 34623795 A JP34623795 A JP 34623795A JP H08239364 A JPH08239364 A JP H08239364A
Authority
JP
Japan
Prior art keywords
acetyl
trimethyl
dihydropyridine
general formula
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7346237A
Other languages
English (en)
Japanese (ja)
Inventor
Klaus Urbahns
クラウス・ウルバーンス
Hans-Georg Heine
ハンス−ゲオルク・ハイネ
Thomas Glaser
トーマス・グラザー
Reilinde Wittka
ライリンデ・ビツトカ
Vry Jean-Marie-Viktor De
ジヤン−マリー−ビクトル・デ・ブリ
Henning Sommermeyer
ヘニング・ゾマーマイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JPH08239364A publication Critical patent/JPH08239364A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP7346237A 1994-12-16 1995-12-13 ５−アシル−１，４−ジヒドロピリジンの使用法 Pending JPH08239364A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4444864A DE4444864A1 (de) 1994-12-16 1994-12-16 Verwendung von 5-Acyl-1,4-dihydropyridinen
DE4444864.3 1994-12-16

Publications (1)

Publication Number Publication Date
JPH08239364A true JPH08239364A (ja) 1996-09-17

Family

ID=6535989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7346237A Pending JPH08239364A (ja) 1994-12-16 1995-12-13 ５−アシル−１，４−ジヒドロピリジンの使用法

Country Status (25)

Country Link
US (2) US5646166A (de)
EP (1) EP0717036B1 (de)
JP (1) JPH08239364A (de)
KR (1) KR960022464A (de)
CN (1) CN1130505A (de)
AT (1) ATE177735T1 (de)
AU (1) AU704466B2 (de)
CA (1) CA2165130A1 (de)
CZ (1) CZ332995A3 (de)
DE (2) DE4444864A1 (de)
DK (1) DK0717036T3 (de)
EE (1) EE9500075A (de)
ES (1) ES2130506T3 (de)
FI (1) FI956015L (de)
GR (1) GR3030319T3 (de)
HU (1) HUT74185A (de)
IL (1) IL116387A (de)
NO (1) NO309125B1 (de)
NZ (1) NZ280662A (de)
PL (1) PL311845A1 (de)
RU (1) RU2158259C2 (de)
SI (1) SI0717036T1 (de)
SK (1) SK158195A3 (de)
TW (1) TW381023B (de)
ZA (1) ZA9510693B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1459500A (en) * 1998-10-28 2000-05-15 Abbott Laboratories Dihydropyridine compounds and methods of use
ATE340795T1 (de) * 2001-01-30 2006-10-15 Lilly Co Eli Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US20050075359A1 (en) * 2003-03-14 2005-04-07 Rikako Kono Large conductance calcium-activated K channel opener
EP1858325A4 (de) * 2005-01-07 2010-06-30 Roskamp Res Llc Verbindungen zur hemmung der beta-amyloidproduktion und verfahren zum identifizieren dieser verbindungen
CN103998038A (zh) * 2011-11-24 2014-08-20 里皮达特发展研究及咨询公司 具有hsp调节活性的1,4-二氢吡啶衍生物
CN103420900B (zh) * 2012-05-22 2015-06-03 中国科学院大连化学物理研究所 一种制备卤代-1,2-二氢吡啶的方法
CN103420901B (zh) * 2012-05-22 2015-06-17 中国科学院大连化学物理研究所 一种制备1,2-二氢吡啶衍生物的方法
CN103804286B (zh) * 2012-11-06 2016-07-06 中国科学院大连化学物理研究所 一种由3-氮杂-1,5-烯炔制备吡啶衍生物的方法
CN103804283B (zh) * 2012-11-06 2016-04-20 中国科学院大连化学物理研究所 一种制备1,2-二氢吡啶衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966948A (en) 1970-01-24 1976-06-29 Bayer Aktiengesellschaft Spasmolytic, vaso-dilating and anti-hypertensive compositions and methods
DE2018738A1 (en) 1970-04-18 1971-10-28 Farbenfabriken Bayer Ag, 5090 Leverkusen Hydrogenated pyridines, quinolines andacridi
DE2018739A1 (en) 1970-04-18 1971-10-28 Farbenfabriken Bayer Ag, 5090 Leverkusen 1,4-dihydro-3,5-diacyl-4-arylpyridines,coronary active
GB1430961A (en) * 1972-01-22 1976-04-07 Yamanouchi Pharma Co Ltd 1-substituted-1,4-dihyddrypyridine derivatives
DE3244178A1 (de) * 1982-11-30 1984-05-30 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
FR2649395B1 (fr) * 1989-07-04 1992-11-06 Adir Nouveau derive de la dihydro-1,4 pyridine denomme (-) Ÿi1Ÿ(((amino-2 ethoxy)-2 ethoxy) methylŸi1Ÿ) -2 (dichloro-2,3 phenyl)-4 ethoxycarbonyl-3 methoxycarbonyl-5 methyl-6 dihydro-1,4 pyridine, son procede de preparation et les compositions qui le contiennent
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
JP3709997B2 (ja) * 1994-03-29 2005-10-26 日東電工株式会社 耐熱性ネガ型フォトレジスト組成物および感光性基材、ならびにネガ型パターン形成方法

Also Published As

Publication number Publication date
AU704466B2 (en) 1999-04-22
CN1130505A (zh) 1996-09-11
RU2158259C2 (ru) 2000-10-27
NZ280662A (en) 1997-02-24
IL116387A0 (en) 1996-03-31
FI956015A0 (fi) 1995-12-14
SK158195A3 (en) 1996-09-04
DE59505373D1 (de) 1999-04-22
US5942526A (en) 1999-08-24
TW381023B (en) 2000-02-01
ES2130506T3 (es) 1999-07-01
HUT74185A (en) 1996-11-28
US5646166A (en) 1997-07-08
CZ332995A3 (en) 1996-07-17
EP0717036A1 (de) 1996-06-19
NO309125B1 (no) 2000-12-18
DK0717036T3 (da) 1999-10-11
FI956015A7 (fi) 1996-06-17
FI956015L (fi) 1996-06-17
GR3030319T3 (en) 1999-09-30
DE4444864A1 (de) 1996-06-20
EP0717036B1 (de) 1999-03-17
KR960022464A (ko) 1996-07-18
EE9500075A (et) 1996-06-17
AU4029395A (en) 1996-06-27
CA2165130A1 (en) 1996-06-17
ZA9510693B (en) 1996-07-03
HU9503592D0 (en) 1996-02-28
NO955104L (no) 1996-06-17
SI0717036T1 (en) 1999-06-30
NO955104D0 (no) 1995-12-15
PL311845A1 (en) 1996-06-24
ATE177735T1 (de) 1999-04-15
IL116387A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
JPS6132308B2 (de)
US6194428B1 (en) Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system
US5426106A (en) Pyrrolo-pyridazinone derivatives
JPH08239364A (ja) ５−アシル−１，４−ジヒドロピリジンの使用法
US5861394A (en) Use of N-substituted phenothiazines
US6121284A (en) 2,3-bridged 1,4-dihydropyridines, and their use as medicaments
DE60015146T2 (de) Serotonerge benzothiophene
JPH10502649A (ja) ジオキソ−チオピラノ−ピリジン−カルボン酸誘導体および薬剤としてのそれらの使用
JPH08239384A (ja) １，２−架橋１，４−ジヒドロピリジンの薬剤としての使用法
WO1997010210A1 (en) Tricyclic pyrrolidine derivatives as calcium channel antagonists
US5874462A (en) Use of substituted 6-amino-4H-pyrans
WO2004043952A1 (fr) Nouveaux derives de 2,3-dihydro-4(1h)-pyridinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5719181A (en) Use of acyl-substituted aminopyrans
US4348395A (en) 1,4-Dihydropyridazine compounds
JPH0959271A (ja) 置換４ｈ−ピラン類
JP2000501409A (ja) ５―ナフタレン―１―イル―１，３―ジオキサン誘導体、その製造およびその治療上の用途
JPH07196615A (ja) アリール−置換されたアルコキシカルボニル−１，４−ジヒドロピリジン−５−カルボン酸エステル類
JPH0859654A (ja) 中枢神経系治療用薬剤としての６−アミノ−１，４−ジヒドロピリジン類の使用およびそれらの製造方法